Clinicopathologic features and contralateral breast cancer risk in BRCA1/2 pathogenic variant carriers: a multicenter registry study of Japanese women.

IF 3 3区 医学 Q2 ONCOLOGY
Breast Cancer Research and Treatment Pub Date : 2025-11-01 Epub Date: 2025-09-06 DOI:10.1007/s10549-025-07815-2
Kanae Taruno, Hiroki Den, Mieko Takeuchi, Mayuko Inuzuka, Masami Arai, Seigo Nakamura, Takanori Ishida
{"title":"Clinicopathologic features and contralateral breast cancer risk in BRCA1/2 pathogenic variant carriers: a multicenter registry study of Japanese women.","authors":"Kanae Taruno, Hiroki Den, Mieko Takeuchi, Mayuko Inuzuka, Masami Arai, Seigo Nakamura, Takanori Ishida","doi":"10.1007/s10549-025-07815-2","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This large-scale study presents the clinicopathological characteristics and cumulative incidence of contralateral breast cancer (CBC) in Japanese BRCA1/2 pathogenic variant carriers, including cases diagnosed after the implementation of national insurance coverage.</p><p><strong>Methods: </strong>We analyzed 2949 breast cancer cases from the registry database of the Japanese Organization of Hereditary Breast and Ovarian Cancer.</p><p><strong>Results: </strong>BRCA1 carriers predominantly developed triple-negative breast cancer, whereas BRCA2 carriers more frequently developed luminal-type tumors, with a younger age of onset observed in BRCA1 carriers. No significant clinicopathological differences were found between the age groups. The cumulative incidence of CBC was 10.0% at five years and 29.0% at 10 years among BRCA1 carriers and 14.0% at five years and 19.0% at 10 years among BRCA2 carriers. CBC was observed in all age groups, including older patients. These findings highlight the importance of individualized decision-making in surgical planning and surveillance strategies.</p><p><strong>Conclusions: </strong>This study included a broad age range of patients, reflecting real-world data following the expansion of insurance coverage in Japan. Further case studies and long-term follow-up are warranted. Our findings support the development of appropriate clinical care and preventive strategies for BRCA1/2 carriers in Japan.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"277-288"},"PeriodicalIF":3.0000,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10549-025-07815-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/6 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: This large-scale study presents the clinicopathological characteristics and cumulative incidence of contralateral breast cancer (CBC) in Japanese BRCA1/2 pathogenic variant carriers, including cases diagnosed after the implementation of national insurance coverage.

Methods: We analyzed 2949 breast cancer cases from the registry database of the Japanese Organization of Hereditary Breast and Ovarian Cancer.

Results: BRCA1 carriers predominantly developed triple-negative breast cancer, whereas BRCA2 carriers more frequently developed luminal-type tumors, with a younger age of onset observed in BRCA1 carriers. No significant clinicopathological differences were found between the age groups. The cumulative incidence of CBC was 10.0% at five years and 29.0% at 10 years among BRCA1 carriers and 14.0% at five years and 19.0% at 10 years among BRCA2 carriers. CBC was observed in all age groups, including older patients. These findings highlight the importance of individualized decision-making in surgical planning and surveillance strategies.

Conclusions: This study included a broad age range of patients, reflecting real-world data following the expansion of insurance coverage in Japan. Further case studies and long-term follow-up are warranted. Our findings support the development of appropriate clinical care and preventive strategies for BRCA1/2 carriers in Japan.

BRCA1/2致病变异携带者的临床病理特征和对侧乳腺癌风险:一项针对日本女性的多中心登记研究
目的:本大规模研究旨在了解日本BRCA1/2致病变异携带者对侧乳腺癌(CBC)的临床病理特征和累积发病率,包括实施国民保险后诊断的病例。方法:对日本遗传性乳腺癌和卵巢癌组织登记数据库中2949例乳腺癌病例进行分析。结果:BRCA1携带者主要发展为三阴性乳腺癌,而BRCA2携带者更频繁地发展为发光型肿瘤,BRCA1携带者的发病年龄更年轻。各年龄组间无明显临床病理差异。BRCA1携带者5年累积CBC发病率为10.0%,10年累积CBC发病率为29.0%,BRCA2携带者5年累积CBC发病率为14.0%,10年累积CBC发病率为19.0%。在所有年龄组(包括老年患者)均观察到CBC。这些发现强调了个体化决策在手术计划和监测策略中的重要性。结论:这项研究包括了广泛的年龄范围的患者,反映了日本保险覆盖范围扩大后的真实数据。进一步的案例研究和长期随访是必要的。我们的研究结果为日本BRCA1/2携带者制定适当的临床护理和预防策略提供了支持。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.80
自引率
2.60%
发文量
342
审稿时长
1 months
期刊介绍: Breast Cancer Research and Treatment provides the surgeon, radiotherapist, medical oncologist, endocrinologist, epidemiologist, immunologist or cell biologist investigating problems in breast cancer a single forum for communication. The journal creates a "market place" for breast cancer topics which cuts across all the usual lines of disciplines, providing a site for presenting pertinent investigations, and for discussing critical questions relevant to the entire field. It seeks to develop a new focus and new perspectives for all those concerned with breast cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信